Rifaximin Use Linked to Daptomycin Resistance: Implications for Antibiotic Stewardship

By João L. Carapinha

October 25, 2024

The article published in Nature, titled “Rifaximin Prophylaxis Causes Resistance to the Last-Resort Antibiotic Daptomycin,” reveals critical findings regarding the use of rifaximin and its impact on antibiotic resistance, particularly concerning the last-resort antibiotic daptomycin. This study suggests that the use of rifaximin, commonly administered to prevent hepatic encephalopathy in patients with liver disease, may inadvertently contribute to the emergence of resistance against daptomycin.

Key Findings:

Rifaximin, a commonly prescribed antibiotic for liver disease, has been found to cause resistance to daptomycin. This is a critical finding as daptomycin is considered a last-resort antibiotic for treating infections caused by vancomycin-resistant enterococcus faecium (VRE), a dangerous superbug.

This is the first recorded instance of one antibiotic causing resistance to another in a different class. Previously, it was believed that antibiotic resistance was limited to the specific antibiotic being used.

Rifaximin was previously considered a “low risk” antibiotic in terms of resistance development. This study challenges that assumption and highlights the unexpected consequences of antibiotic use.

Specific mutations in the rpoB gene of VRE are responsible for this cross-resistance. These mutations are becoming increasingly prevalent globally, coinciding with the increased use of rifaximin.

Rifaximin exposure leads to the upregulation of the prdRAB operon in VRE. It results in cell membrane changes that reduce daptomycin binding and efficacy. This newly identified mechanism is independent of previously known daptomycin resistance mechanisms.

This research highlights the unintended consequences of using rifaximin prophylactically. Notably, its role in promoting resistance to critical antibiotics like daptomycin. Such findings carry significant implications for public health and antibiotic stewardship, highlighting the urgent need for careful management of antibiotic use to reduce the development of antibiotic resistance. The interplay between rifaximin and daptomycin resistance emphasizes the importance of ongoing monitoring and evaluation of antibiotic prescribing practices.

Reference url

Recent Posts

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.